Tuesday, September 1, 2026

University of Oxford develops new Ebola vaccine 

The vaccine would be assessed for safety and immune response in 50 healthy adults in the UK aged between 18 and 55.

• July 13, 2026
A medical lab technician at work
A medical lab technician at work[Credit: ASM]

Scientists at the University of Oxford have developed a vaccine against the Bundibugyo strain of Ebola.

The vaccine would be assessed for safety and immune response in 50 healthy adults in the UK aged between 18 and 55.

To support the “rapid launch of the study and progression of the vaccine candidate into clinical evaluation”, some 620,000 doses of the ChAdOx1 BDBV vaccine for potential future use have been stockpiled.

Some 4,000 investigational doses have also been supplied for the Oxford trial, while researchers are also working with partners in Uganda to prepare for trials in Africa.

Volunteers will be monitored for a year, but scientists expect to know quickly whether the jab could provide people with good protection.

The new vaccine uses the same technology as the Oxford/AstraZeneca Covid-19 vaccine, meaning it could be developed in weeks.

Professor Teresa Lambe, the study’s lead scientific investigator, said, “The ongoing Bundibugyo Ebola virus outbreak continues to devastate affected communities, underlining the urgent need for effective vaccines and treatments.

“Our team has worked tirelessly with global partners to develop a candidate ChAdOx BDBV vaccine, demonstrating how collaborative partnerships can enable rapid response in the face of rapidly evolving outbreaks.

“This milestone comes after only 57 days since the World Health Organisation declared the outbreak a public health emergency of international concern.”

Dr Nicole Lurie, executive director of preparedness and response at the Coalition for Epidemic Preparedness Innovations (CEPI), said, “The deadly Bundibugyo epidemic is already the third-largest Ebola outbreak on record, and infection numbers are continuing to rise.

“The University of Oxford’s work to progress their Bundibugyo vaccine candidate, ready to enter Phase I trials in a matter of weeks, is a pivotal milestone in the response effort.

“Every step that brings a safe and effective vaccine closer helps strengthen our ability to protect vulnerable communities, save lives and bring this outbreak under control.”

(Reuters/NAN)

We have recently deactivated our website's comment provider in favour of other channels of distribution and commentary. We encourage you to join the conversation on our stories via our Facebook, Twitter and other social media pages.

More from Peoples Gazette

farmers

Agriculture

FG tasks ECOWAS on leveraging financing strategies for agroecology

The federal government has urged stakeholders in the agriculture and finance sectors in the West Africa region to leverage financing strategies to enhance agroecology practices

Katsina State

Politics

Katsina youths pledge to deliver over 2 million votes to Atiku

“Katsina State is Atiku’s political base because it is his second home.”

Flooding in Nepal

Hot news Home top

Nepal flood death toll climbs to 1,000, 4,400 missing

Bodies of over 102 Nepali soldiers, police, and customs officers were recovered from the floods.

Intellectual property

NationWide

Experts advocate increased awareness on intellectual property

Mr Husseini acknowledged the widespread lack of awareness about IP rights and regulations.

National Human Rights Commission (NHRC)

States

NHRC ‌⁠‍‍⁠⁠‌‍⁠⁠‌‍‍‌woos Gombe to bolster human rights

The coordinator commended the state government’s efforts at advancing the wellbeing of the people.

The tricycle ambulances

Hot news Home top

FG begins nationwide distribution of life support ambulances, others 

Mr Mutwang described the ambulances as a strategic investment in emergency healthcare.

Global bonds

Heading 2

Global bond sell-off rises as oil prices trigger inflation

Renewed fighting between the U.S. and Iran over the weekend pushed oil prices higher, with Brent crude rising above $90 a barrel and reaching about $92 on Tuesday.